Alessandro Sannino
Corporate Officer/Principal bei University of Salento
Vermögen: 2 410 $ am 31.12.2023
Aktive Positionen von Alessandro Sannino
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Salento | Corporate Officer/Principal | 01.09.2000 | - |
Karriereverlauf von Alessandro Sannino
Ehemalige bekannte Positionen von Alessandro Sannino
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GELESIS HOLDINGS, INC. | Corporate Officer/Principal | 13.01.2022 | 30.10.2023 |
| GELESIS INC | Corporate Officer/Principal | 01.05.2008 | 01.01.2022 |
Academica Life Science SRL
 Academica Life Science SRL Miscellaneous Commercial ServicesCommercial Services Academica Life Science SRL develops biodegradable superabsorbent hydro gels. The company was founded by Luigi Ambrosio, Luigi Nicolais and Alessandro Sannino in 2006 and is headquartered in Naples, Italy | Gründer | 26.05.2010 | - |
| Präsident | 01.04.2006 | - |
Ausbildung von Alessandro Sannino
| Università degli Studi di Napoli Federico II | Doctorate Degree |
| University of Washington | Doctorate Degree |
Statistik
International
| Italien | 4 |
| Vereinigte Staaten | 4 |
Operativ
| Corporate Officer/Principal | 3 |
| Doctorate Degree | 2 |
| Founder | 1 |
Sektoral
| Consumer Services | 4 |
| Health Technology | 3 |
| Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GELESIS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Academica Life Science SRL
Academica Life Science SRL Miscellaneous Commercial ServicesCommercial Services Academica Life Science SRL develops biodegradable superabsorbent hydro gels. The company was founded by Luigi Ambrosio, Luigi Nicolais and Alessandro Sannino in 2006 and is headquartered in Naples, Italy | Commercial Services |
Gelesis, Inc.
 Gelesis, Inc. BiotechnologyHealth Technology Gelesis, Inc. operates as a consumer-centered biotherapeutics company, which engages in the development of novel therapies to induce weight loss and metabolic disorders. Its commercial product portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease /Non-alcoholic Steatohepatitis, and Functional Constipation. The company was founded by Yishai Zohar in 2006 and is headquartered in Boston, MA. | Health Technology |
- Börse
- Insiders
- Alessandro Sannino
- Erfahrung
